公开(公告)号：EP3634951B8

公开(公告)日：2024-08-21

申请号：EP18739634.6

申请日：2018-06-08

IPC: C07D213/76 ,  C07D319/18 ,  C07D231/38 ,  C07D333/34 ,  C07C381/10 ,  C07D295/096 ,  C07D305/08 ,  C07D213/70 ,  C07D307/64 ,  A61K31/4406 ,  A61P29/00 ,  C07D215/36

CPC classification number: C07D213/76 ,  C07D215/36 ,  C07D319/18 ,  C07D231/38 ,  C07D333/34 ,  C07C381/10 ,  C07D295/096 ,  C07D305/08 ,  C07D213/70 ,  C07D307/64 ,  C07C2603/1020170501 ,  A61P29/00

公开(公告)号：EP4366832A1

公开(公告)日：2024-05-15

申请号：EP22837147.2

申请日：2022-07-08

Applicant: Zydus Lifesciences Limited

Inventor： AGARWAL, Sameer ,  PARMAR, Deven V. ,  PHILIP, Binu ,  SHARMA, Rajiv ,  JAIN, Mukul ,  CHATTERJEE, Abhijit

IPC: A61P31/18 ,  C07D205/04 ,  C07C311/00

CPC classification number: A61P31/18 ,  C07D333/34 ,  C07D307/64 ,  C07D277/26 ,  C07D233/60 ,  C07D207/08 ,  C07D471/04

公开(公告)号：EP3416956A1

公开(公告)日：2018-12-26

申请号：EP17706871.5

申请日：2017-02-17

Applicant: The Institute of Cancer Research : The Royal Cancer Hospital

Inventor： SPRINGER, Caroline ,  MARAIS, Richard ,  NICULESCU-DUVAZ, Dan ,  LEUNG, Leo ,  SMITHEN, Deborah ,  CALLENS, Cedric ,  TANG, Haoran

IPC: C07D333/34 ,  C07D277/36 ,  A61P29/00

CPC classification number: C07D333/34 ,  C07D263/46 ,  C07D277/36 ,  C07D409/12

Abstract: Provided are compounds of the Formula (I), or a pharmaceutically acceptable salt thereof, wherein W, X, Y, Z, x, R1, R2, R3, x and n are defined in the specification. The compounds are inhibitors of lysyl oxidase (LOX) and lysyl oxidase-like (LOXL) family members (LOXL1, LOXL2, LOXL3, LOXL4) and are useful in therapy, particularly in the treatment of cancer. Also disclosed are LOX inhibitors for use in the treatment of a cancer associated with EGFR and biomarkers that predict responsiveness to a LOX inhibitor.

公开(公告)号：EP3227262A4

公开(公告)日：2018-07-11

申请号：EP15864386

申请日：2015-12-02

Applicant: NOVIRA THERAPEUTICS INC

Inventor： CHEN AUSTIN ,  BRAVO YALDA ,  STOCK NICHOLAS ,  PEDRAM BIJAN ,  JACINTHO JASON ,  CLARK RYAN C ,  TRUONG YEN

IPC: C07C311/24 ,  A61K31/167 ,  A61K31/18 ,  A61K31/192 ,  A61K31/381 ,  A61K31/415 ,  A61K31/44 ,  A61K31/5375 ,  A61K45/06 ,  A61P31/12 ,  C07C323/62 ,  C07D213/81 ,  C07D231/18 ,  C07D333/34 ,  C07D487/10

CPC classification number: C07C323/62 ,  A61K31/167 ,  A61K31/18 ,  A61K31/192 ,  A61K31/341 ,  A61K31/381 ,  A61K31/397 ,  A61K31/415 ,  A61K31/44 ,  A61K31/445 ,  A61K31/4453 ,  A61K31/495 ,  A61K31/5375 ,  A61K45/06 ,  C07C311/03 ,  C07C311/24 ,  C07C2601/02 ,  C07C2601/04 ,  C07C2601/08 ,  C07C2601/14 ,  C07C2601/18 ,  C07C2602/18 ,  C07C2602/20 ,  C07D211/46 ,  C07D213/81 ,  C07D231/18 ,  C07D295/185 ,  C07D305/06 ,  C07D307/10 ,  C07D307/18 ,  C07D309/04 ,  C07D333/34 ,  C07D333/48 ,  C07D405/12 ,  A61K2300/00

Abstract: The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.

公开(公告)号：EP2681209B1

公开(公告)日：2018-05-09

申请号：EP11860054.3

申请日：2011-03-02

Applicant: Aquilus Pharmaceuticals, Inc

Inventor： SUCHOLEIKI, Irving

IPC: C07D233/72 ,  C07D331/02 ,  C07D309/04 ,  C07D309/06 ,  C07D333/34 ,  C07D409/12 ,  C07C43/263 ,  C07C231/12 ,  C07C237/26 ,  C07C237/32 ,  C07C311/19 ,  C07C317/44 ,  A61K31/404 ,  A61K31/12 ,  A61P25/04 ,  A61P23/00

CPC classification number: C07D207/337 ,  A61K31/12 ,  A61K31/404 ,  A61K45/06 ,  C07B2200/05 ,  C07C231/12 ,  C07C237/26 ,  C07C311/19 ,  C07C317/44 ,  C07D209/16 ,  C07D209/48 ,  C07D211/60 ,  C07D233/72 ,  C07D307/85 ,  C07D309/04 ,  C07D309/06 ,  C07D331/02 ,  C07D333/34 ,  C07D409/12 ,  Y02A50/465 ,  A61K2300/00

Abstract: The present invention relates generally to pharmaceutical agents, and in particular, to metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of dual acting MMP-2 and MMP-9 inhibiting compounds that exhibit increased potency, metabolic stability and/or reduced toxicity in relation to currently known MMP-2 and MMP-9 inhibitors for the treatment of pain and other diseases. Additionally, the present invention relates to methods for treating pain, addiction and/or withdrawal symptoms in a patient comprising administering to the patient a pain-reducing effective amount of a present compound.

公开(公告)号：EP2955173B1

公开(公告)日：2017-10-04

申请号：EP15164047.1

申请日：2011-12-12

Applicant: ALLERGAN, INC.

Inventor： Yuan, Haiqing ,  Beard, Richard, L. ,  Liu, Xiaoxia ,  Donello, John E. ,  Viswanath, Veena ,  Garst, Michael E.

IPC: C07D231/18 ,  C07D307/82 ,  C07D333/34 ,  C07D405/12 ,  C07D407/12 ,  C07D409/12 ,  C07D409/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D498/04 ,  C07D513/04 ,  C07C311/44 ,  C07C311/21

CPC classification number: A61K31/381 ,  A61K31/343 ,  A61K31/37 ,  A61K31/404 ,  A61K31/4155 ,  A61K31/4196 ,  A61K31/422 ,  A61K31/423 ,  A61K31/4245 ,  A61K31/427 ,  A61K31/428 ,  A61K31/429 ,  A61K31/4436 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/497 ,  A61K31/498 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/538 ,  A61K31/5383 ,  A61K31/55 ,  A61K31/635 ,  C07C311/21 ,  C07C311/44 ,  C07D231/18 ,  C07D307/82 ,  C07D333/34 ,  C07D405/12 ,  C07D407/12 ,  C07D409/12 ,  C07D409/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D498/04 ,  C07D513/04

公开(公告)号：EP3021839A4

公开(公告)日：2017-05-31

申请号：EP14825819

申请日：2014-07-18

Applicant: BAYLOR COLLEGE MEDICINE

Inventor： TWEARDY DAVID J ,  KASEMBELI MOSES M ,  XU MARVIN X ,  AGARWAL SANDEEP K ,  PEDROZA MESIAS

IPC: A61K31/18 ,  A61K31/05 ,  A61K31/4196 ,  A61K45/06 ,  A61P17/02 ,  A61P35/00

CPC classification number: C07D417/12 ,  A61K31/18 ,  A61K31/343 ,  A61K31/39 ,  A61K31/4196 ,  A61K45/06 ,  C07C317/28 ,  C07C317/30 ,  C07C317/32 ,  C07D213/71 ,  C07D215/06 ,  C07D231/18 ,  C07D239/60 ,  C07D261/10 ,  C07D333/34 ,  C07D409/12 ,  C07D413/12

公开(公告)号：EP3162798A1

公开(公告)日：2017-05-03

申请号：EP16195491.2

申请日：2008-09-24

Applicant: Takeda Pharmaceutical Company Limited

Inventor： NISHIDA, Haruyuki ,  ARIKAWA, Yasuyoshi ,  HIRASE, Keizo

IPC: C07D233/64 ,  A61K31/381 ,  A61K31/4164 ,  A61P1/00 ,  C07D233/68 ,  C07D277/28

CPC classification number: C07D333/20 ,  C07D231/18 ,  C07D231/38 ,  C07D231/40 ,  C07D231/42 ,  C07D233/24 ,  C07D233/42 ,  C07D333/32 ,  C07D333/34 ,  C07D401/12 ,  C07D403/04 ,  C07D409/14 ,  C07D417/06 ,  C07D417/14

Abstract: Provided is a compound having a superior acid secretion suppressive action, which shows an antiulcer activity and the like.
A compound represented by the formula (I) or a salt thereof:

wherein ring A is as defined in claim 1;
R 1 and R 2 are each a cyclic group optionally having substituent(s); R 3 and R 4 are each H or alkyl, or R 3 and R 4 form, together with the adjacent N, an nitrogen-containing heterocycle; and Y is a spacer.

Abstract translation: 提供具有优异的酸分泌抑制作用的化合物，其显示抗溃疡活性等。 由式（I）表示的化合物或其盐：其中环A如权利要求1中所定义; R1和R2各自为任选具有取代基的环状基团; R3和R4各自为H或烷基，或者R3和R4与相邻的N一起形成含氮杂环; Y是间隔子。

公开(公告)号：EP1869009B1

公开(公告)日：2016-06-01

申请号：EP06726734.4

申请日：2006-04-12

Applicant: Vicore Pharma AB

Inventor： ALTERMAN, Mathias ,  HALLBERG, Anders ,  SUBBAIAH, Murugaiah, Andappan, Murugaiah

IPC: C07D333/40 ,  C07D333/34 ,  C07D409/12 ,  A61K31/381 ,  A61P1/00 ,  A61P9/00

CPC classification number: C07D409/12 ,  C07D333/34 ,  C07D333/40

公开(公告)号：EP3021841A1

公开(公告)日：2016-05-25

申请号：EP14826845.1

申请日：2014-07-18

Applicant: Baylor College Of Medicine

Inventor： TWEARDY, David, J. ,  KASEMBELI, Moses, M. ,  XU, Marvin, X. ,  ECKOLS, Thomas, Kristian

IPC: A61K31/18

CPC classification number: C07D333/34 ,  A61K31/145 ,  A61K31/18 ,  A61K31/357 ,  A61K31/381 ,  A61K31/4035 ,  A61K31/404 ,  A61K31/415 ,  A61K31/4164 ,  A61K31/4196 ,  A61K31/42 ,  A61K31/428 ,  A61K31/4406 ,  A61K31/45 ,  A61K31/454 ,  A61K31/47 ,  A61K31/4704 ,  A61K31/4709 ,  A61K31/513 ,  A61K45/06 ,  C07C311/08 ,  C07C311/10 ,  C07C311/13 ,  C07C311/21 ,  C07C311/24 ,  C07C311/29 ,  C07C311/44 ,  C07C323/49 ,  C07C381/06 ,  C07C2101/14 ,  C07C2102/10 ,  C07C2601/14 ,  C07C2602/10 ,  C07D213/71 ,  C07D215/36 ,  C07D231/18 ,  C07D319/18 ,  Y02A50/409

Abstract: Embodiments of the invention include methods of treating, preventing, and/or reduce the risk or severity of a condition selected from the group consisting of muscle wasting, muscle weakness, cachexia, and a combination thereof in an individual in need thereof. In some embodiments, particular small molecules are employed for treatment, prevention, and/or reduction in the risk of muscle wasting. In at least particular cases, the small molecules are inhibitors of STAT3.